Effects of targeting disease and medication management interventions towards patients with COPD

References

• Bischoff EW, Akkermans R, Bourbeau J, et al. Comprehensive self management and routine monitoring in chronic obstructive pulmonary disease patients in general practice: randomised controlled trial. BMJ 2012;345:e7642
   Google Scholar
• Chavannes NH, Grijsen M, van den Akker M, et al. Integrated disease management improves one-year quality of life in primary care COPD patients: a controlled clinical trial. Prim Care Respir J 2009;18:171-6
   PubMedGoogle Scholar
• Kruis AL, Boland MR, Assendelft WJ, et al. Effectiveness of integrated disease management for primary care chronic obstructive pulmonary disease patients: results of cluster randomised trial. BMJ 2014;349:g5392
   PubMed Web of Science ®Google Scholar
• Zhou Y, Hu G, Wang D, et al. Community based integrated intervention for prevention and management of chronic obstructive pulmonary disease (COPD) in Guangdong, China: cluster randomised controlled trial. BMJ 2010;341:c6387
   PubMed Web of Science ®Google Scholar
• Bourbeau J. Not all self-management programs in chronic obstructive pulmonary disease have positive results: why is replication a problem? Chron Respir Dis 2004;1:5-6
   PubMedGoogle Scholar
• van Boven JF, Chavannes NH, van der Molen T, et al. Clinical and economic impact of non-adherence in COPD: A systematic review. Respir Med 2014;108:103-13
   PubMed Web of Science ®Google Scholar
• Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011;105:930-8
   PubMed Web of Science ®Google Scholar
• Lareau SC, Yawn BP. Improving adherence with inhaler therapy in COPD. Int J Chron Obstruct Pulmon Dis 2010;5:401-6
   PubMedGoogle Scholar
• Tommelein E, Mehuys E, Van Hees T, et al. Effectiveness of pharmaceutical care for patients with chronic obstructive pulmonary disease (PHARMACOP): a randomized controlled trial. Br J Clin Pharmacol 2014;77:756-66
   PubMed Web of Science ®Google Scholar
• van Boven JF, Tommelein E, Boussery K, et al. Improving inhaler adherence in patients with chronic obstructive pulmonary disease: a cost-effectiveness analysis. Respir Res 2014;15:66
   PubMed Web of Science ®Google Scholar
• Bryant J, McDonald VM, Boyes A, et al. Improving medication adherence in chronic obstructive pulmonary disease: a systematic review. Respir Res 2013;14:109
   PubMed Web of Science ®Google Scholar
• Zwerink M, Brusse-Keizer M, van der Valk PD, et al. Self management for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014;3:CD002990
   PubMed Web of Science ®Google Scholar
• Vegter S, Oosterhof P, van Boven JF, et al. Improving adherence to lipid-lowering therapy in a community pharmacy intervention program: a cost-effectiveness analysis. J Manag Care Spec Pharm 2014;20:722-32
   PubMed Web of Science ®Google Scholar
• Stuurman-Bieze AG, Hiddink EG, van Boven JF, Vegter S. Proactive pharmaceutical care interventions decrease patients' nonadherence to osteoporosis medication. Osteoporos Int 2014;25:1807-12
   PubMed Web of Science ®Google Scholar
• Stuurman-Bieze AG, Hiddink EG, van Boven JF, Vegter S. Proactive pharmaceutical care interventions improve patients' adherence to lipid-lowering medication. Ann Pharmacother 2013;47:1448-56
   PubMed Web of Science ®Google Scholar
• van Boven JF, Stuurman-Bieze AG, Hiddink EG, et al. Medication monitoring and optimization: a targeted pharmacist program for effective and cost-effective improvement of chronic therapy adherence. J Manag Care Pharm 2014;20:786-92
   PubMed Web of Science ®Google Scholar
• Casas A, Troosters T, Garcia-Aymerich J, et al. Integrated care prevents hospitalisations for exacerbations in COPD patients. Eur Respir J 2006;28:123-30
   PubMed Web of Science ®Google Scholar
• Sridhar MK, Galloway A, Lean ME, Banham SW. An out-patient nutritional supplementation programme in COPD patients. Eur Respir J 1994;7:720-4
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-38
   PubMed Web of Science ®Google Scholar
• van der Molen T, Willemse BW, Schokker S, et al. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes 2003;1:13
   PubMedGoogle Scholar
• Kocks JW, Tuinenga MG, Uil SM, et al. Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire. Respir Res 2006;7:62
   PubMed Web of Science ®Google Scholar
• EuroQol Group. EuroQol – a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208
   PubMed Web of Science ®Google Scholar
• Bestall JC, Paul EA, Garrod R, et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999;54:581-6
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet 2007;370:786-96
   PubMed Web of Science ®Google Scholar
• Akinbami LJ, Sullivan SD, Campbell JD, et al. Asthma outcomes: healthcare utilization and costs. J Allergy Clin Immunol 2012;129(3 Suppl):S49-64
   PubMed Web of Science ®Google Scholar
• GIP databank. Available at: www.gipdatabank.nl [Last accessed 6 May 2015]
   Google Scholar
• Health Care Insurance Board. Dutch pharmacoeconomic guidelines [in Dutch]. Available at: http://www.zorginstituutnederland.nl/binaries/content/documents/zinl-www/documenten/publicaties/publications-in-english/2006/0604-guidelines-for-pharmacoeconomic-research/0604-guidelines-for-pharmacoeconomic-research/Guidelines+for+pharmacoeconomic+research.pdf [Last accessed 24 July 2015]
   Google Scholar
• Taitel MS, Sanchez RJ, Fensterheim LE, et al. Pharmacist-delivered interventions impact on target and non-target chronic medication adherence. Am J Pharm Benefits 2014;6:115-24
   Google Scholar
• Vestbo J, Anderson JA, Calverley PM, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax 2009;64:939-43
   PubMed Web of Science ®Google Scholar
• Boland MR, van Boven JF, Kocks JW, et al. Mapping the clinical chronic obstructive pulmonary disease questionnaire onto generic preference-based EQ-5D values. Value Health 2015;18:299-307
   PubMed Web of Science ®Google Scholar
• Ringbaek T, Brondum E, Martinez G, Lange P. EuroQoL in assessment of the effect of pulmonary rehabilitation COPD patients. Respir Med 2008;102:1563-7
   PubMed Web of Science ®Google Scholar
• Takemura M, Mitsui K, Ido M, et al. Effect of a network system for providing proper inhalation technique by community pharmacists on clinical outcomes in COPD patients. Int J Chron Obstruct Pulmon Dis 2013;8:239-44
   PubMed Web of Science ®Google Scholar
• Khdour MR, Kidney JC, Smyth BM, McElnay JC. Clinical pharmacy-led disease and medicine management programme for patients with COPD. Br J Clin Pharmacol 2009;68:588-98
   PubMed Web of Science ®Google Scholar
• Leiva-Fernandez J, Leiva-Fernandez F, Garcia-Ruiz A, et al. Efficacy of a multifactorial intervention on therapeutic adherence in patients with chronic obstructive pulmonary disease (COPD): a randomized controlled trial. BMC Pulm Med 2014;14:70
   PubMed Web of Science ®Google Scholar
• Mannino DM, Higuchi K, Yu TC, et al. Economic burden of chronic obstructive pulmonary disease by presence of comorbidities. Chest 2015;148:138-50
   PubMed Web of Science ®Google Scholar
• D'Arcy S, MacHale E, Seheult J, et al. A method to assess adherence in inhaler use through analysis of acoustic recordings of inhaler events. PLoS One 2014;9:e98701
   PubMed Web of Science ®Google Scholar
• Van Boven JF, Trappenburg JC, van der Molen T, Chavannes NH. Towards tailored and targeted adherence assessment to optimise asthma management. NPJ Prim Care Respir Med 2015;25:15046
   PubMed Web of Science ®Google Scholar
• van Boven JF, Vegter S, van der Molen T, Postma MJ. COPD in the working age population: the economic impact on both patients and government. COPD 2013;10:629-39
   PubMedGoogle Scholar